- Conditions
- Breast Carcinoma, Pain, Radiation-Induced Dermatitis, Stage 0 Breast Cancer
- Interventions
- Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Gary Morrow
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Newark, Delaware • Decatur, Illinois • Minneapolis, Minnesota + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 10,845
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- delandistrogene moxeparvovec, placebo
- Genetic
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 7 Years · Male only
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 20 more
- Conditions
- Acute Blunt Soft Tissue Injuries/Contusions
- Interventions
- placebo, Placebos
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 10
- States / cities
- Bradenton, Florida • Port Orange, Florida • Boise, Idaho + 7 more
- Conditions
- Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
- Interventions
- Docetaxel, HyperAcute®-Lung Immunotherapy, Gemcitabine, Pemetrexed
- Drug · Biological
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 24
- States / cities
- Santa Rosa, California • Stamford, Connecticut • Gainesville, Florida + 20 more
- Conditions
- Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
- Interventions
- Kidney Biopsy
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Up to 80 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2030
- U.S. locations
- 39
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Interventions
- gefitinib
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 95
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
- Conditions
- Adolescents, Mental Disorder Diagnosed in Childhood, Suicide Prevention
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • Columbus, Ohio
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 102
- States / cities
- Vestavia Hills, Alabama • Glendale, Arizona • Mesa, Arizona + 90 more
- Conditions
- COVID-19
- Interventions
- Hydroxychloroquine, Placebo oral tablet
- Drug
- Lead sponsor
- Adrian Hernandez
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 34
- States / cities
- Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more
- Conditions
- Sarcoidosis; Antimycobacterial Therapy
- Interventions
- Levofloxacin, Ethambutol, Azithromycin, Rifampin, Placebo
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 6
- States / cities
- Albany, New York • Cincinnati, Ohio • Cleveland, Ohio + 3 more
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma
- Interventions
- Cancer Screening, Discussion, Educational Activity, Educational Intervention, Focus Group, Health Care Delivery, Health Promotion, Health Promotion and Education, Health Risk Assessment, Implementation, Informational Intervention, Internet-Based Intervention, Interview, Outreach, Patient Navigation, Survey Administration
- Other · Behavioral · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 2,067 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Clinical Observation, Cyclophosphamide, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Prednisone, Therapeutic Immune Globulin
- Other · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 8 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2022
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 78 more
- Conditions
- Fibromyalgia
- Interventions
- pregabalin
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Santa Ana, California • Miami, Florida + 12 more
- Conditions
- Muscular Dystrophy, Duchenne
- Interventions
- Spironolactone, Prednisolone
- Drug
- Lead sponsor
- Kevin Flanigan
- Other
- Eligibility
- 4 Years to 7 Years · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Iowa City, Iowa • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
- Conditions
- Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
- Interventions
- Bortezomib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-445/TEZ/IVA, IVA, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 53
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 48 more
- Conditions
- Abdominal Aortic Aneurysm (AAA)
- Interventions
- Subjects who receive the Treovance stent-graft
- Device
- Lead sponsor
- Bolton Medical
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Danbury, Connecticut + 24 more
- Conditions
- Functional Gastrointestinal Disorders
- Interventions
- Amoxicillin, Placebo
- Drug · Other
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow
- Interventions
- Quantitative Myocardial Blood Flow Evaluation, Qualitative Myocardial Blood Flow Evaluation, Gadavist, Vasodilator, Blood draw for the laboratory assessment
- Diagnostic Test · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- San Francisco, California • Louisville, Kentucky • Boston, Massachusetts + 9 more
- Conditions
- Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration, Pulmonary Valve; Obstruction
- Interventions
- SAPIEN 3 THV
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 15 more
- Conditions
- Parkinson Disease, Dystonia, Tremors, Obsessive Compulsive Disorder, Depression
- Interventions
- No intervention
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 7 Years to 90 Years
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
- Interventions
- Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 49 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
- Conditions
- Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
- Interventions
- Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine, Quizartinib
- Drug
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more
- Conditions
- MPOX
- Interventions
- Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 719 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more